At yesterday’s AACR (American Association of Cancer Research) Meeting in Washington DC researchers presented results from the Battle Trial which is a hypothesis- driven prospective study that identifies biomarkers(BM’s) to predict tumor response and thus helps select personalized therapy for lung cancer patients.Biopsy specimens were tested for eleven biomarkers from four NSCLS pathways:EGFR,KRAS,BRAF and VEGF.The Conclusion was that the BATTLE study establishes a new paradigm to investigate BM’s and molecularly targeted treatments in lung cancer patients.
| Abstract Number: | LB-1 |
| Presentation Title: | The BATTLE trial (Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination): personalizing therapy for lung cancer |
| Presentation Time: | Sunday, Apr 18, 2010, 11:25 AM -11:45 AM |
| Location: | Exhibit Hall D, Washington Convention Center |
| Author Block: | Edward S. Kim, Roy S. Herbst, J Jack Lee, George R. Blumenschein Jr., Anne Tsao, Christine M. Alden, Ximing Tang, Suyu Liu, David J. Stewart, John V. Heymach, Hai T. Tran, Marshall E. Hicks, Jeremy Erasmus Jr., Sanjay Gupta, Garth Powis, Scott M. Lippman, Ignacio I. Wistuba, Waun K. Hong. University of Texas M. D. Anderson Cancer Center, Houston, TX |
Related news on the subject:
Onyx Drug Shows Broader Potential in Cancer Studies (Update2) – Bloomberg.com
